Are you Dr. Hortobagyi?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 107 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Summary
- Dr. Gabriel Hortobagyi, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Florida, and Ohio. He is affiliated with University of Texas M.D. Anderson Cancer Center and is a Professor of Medicine at University Tex Houston.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1974 - 1976
Columbia Saint Luke's Medical CenterResidency, Internal Medicine, 1971 - 1974
National University of ColombiaClass of 1970
Certifications & Licensure
FL State Medical License 2021 - Present
TX State Medical License 1975 - 2026
OH State Medical License 1974 - 2018
PA State Medical License 1973 - 1978- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2003-2014
- Top Doctors:SE Texas Castle Connolly, 2013
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Clinical Trials
- S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer Start of enrollment: 2005 Sep 01
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
- Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Publications & Presentations
PubMed
- Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast Cancer.Lajos Pusztai, Jess R Hoag, Kathy S Albain, William E Barlow, Salomon M Stemmer
Journal of Clinical Oncology. 2024-12-02 - Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer: A Review.Paolo Tarantino, Gabriel Hortobagyi, Sara M Tolaney, Elizabeth A Mittendorf
JAMA Oncology. 2024-11-01 - Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study.Clinton Yam, Miral Patel, Holly A Hill, Ryan Sun, Roland L Bassett Jr
Cancer Research Communications. 2024-10-01
Press Mentions
World Cancer Day 2023: All You Need to KnowFebruary 4th, 2023- 22 Research Highlights from the Past YearDecember 19th, 2022
- Novartis : NEJM Publication of Novartis Kisqali® Data Shows Longest Median Overall Survival Ever Reported in HR+/HER2- Advanced Breast CancerMarch 14th, 2022
- Join now to see all
Grant Support
- Developmental Reseach ProgramNational Cancer Institute2008–2009
- Career Development ProgramNational Cancer Institute2008–2009
- Administrative CoreNational Cancer Institute2008–2009
- Utmdacc Spore In Breast CancerNational Cancer Institute2005–2009
- Specialized Program Of Research Excellence/Breast CancerNational Cancer Institute1992–1994
Professional Memberships
- Fellow
